ClinicalTrials.gg
RecruitingNCT05036707Updated Sep 22, 2026

Human Immune Response to Ixodes Scapularis Tick Bites

A Phase 1/2 interventional study of Xenodiagnosis Ticks and skin biopsy in Tick-borne Diseases, Tick Resistance and Lyme Disease, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Recruiting at 1 site in United States. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-22.

Primary conditionLyme DiseaseRegistry: Tick-Borne DiseasesReclassifiedWhy we changed it
Registry
Tick-Borne Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lyme Disease
Why
  1. The study's listed conditions name Lyme Disease, a narrower term within Tick-Borne Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 1/2, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Feb 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Lyme Disease by National Institute of Allergy and Infectious Diseases (NIAID) — 3 open to participants now, 3 under way, none of them phase 3. Lyme Disease · National Institute of Allergy and Infectious Diseases (NIAID).

Started
2022
the only one that year
Phase 1/2
Only one
of the 12
Registered
12th of 12
by date

Among the 12 studies in Lyme Disease by National Institute of Allergy and Infectious Diseases (NIAID), this one is the only one that started in 2022, is the only one in phase 1/2, and was the 12th registered.

Lyme Disease

98 studies on the registry are indexed under Lyme Disease; 27 are open to participants now.

Browse Lyme Disease studies →

Open to participants now

3 of the 12 studies in Lyme Disease by National Institute of Allergy and Infectious Diseases (NIAID) are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 18 Lyme Disease studies recruiting now, 11 (61%) set no upper age limit and 3 (17%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Lyme Disease by National Institute of Allergy and Infectious Diseases (NIAID), or all of them as a file.
02

Study summary

Background:

Each year, the number of cases of tick-borne diseases increases. The deer tick (Ixodes scapularis) is the vector of at least 7 pathogens that cause human diseases, including Lyme disease. Researchers want to learn more to help them develop vaccines against ticks in the future.

Objective:

To learn how people s bodies, particularly the skin, respond to tick bites.

Eligibility:

Healthy adults aged 18 years and older who have no known history of a tick-borne disease or tick bite exposure.

Design:

Participants will be screened with a medical history, physical exam, and blood tests.

Participants will have 2 skin punch biopsies of healthy skin. For this, a sharp instrument will be used to remove a round plug of skin about the size of a pencil eraser. Participants will then have 10 clean laboratory-bred ticks placed at 2 different sites on their skin (20 ticks total). The ticks will be removed from the first site 1 day after placement and from the second site 2-4 days after placement. Participants will complete symptom diary cards. They will answer questions about itching at the tick feeding sites. They will give blood samples. Photos will be taken of the tick feeding sites. Skin punch biopsies will be collected at the sites of the tick bites.

Participants will repeat the tick feeding procedures 2 times, each 2-8 weeks apart. For the 2nd and 3rd procedures, 10 clean laboratory-bred ticks will be placed at 1 site. The ticks will be removed 2-3 days after tick placement. They will have telephone follow-up visits after each procedure.

After the final tick removal, participants will have follow-up visits in 4-6 weeks and again in 3 months. They will give blood samples and discuss how they are feeling.

Participation will last about 5-7 months.

Read the detailed description

Study Description:

This study aims to develop a model for acquired tick resistance in humans, characterize the acquisition of tick-associated skin immunity, and monitor the innate and adaptive immune response of Ixodes scapularis tick bites. The study will be a prospective, non-randomized, single-center study performed at the National Institutes of Health (NIH) Clinical Center. It will be performed under Investigational Device Exemption (IDE) G210153 and will be monitored as per National Institute of Allergy and Infectious Diseases (NIAID) and NIH regulations. Participants (35 adult healthy volunteers) will undergo up to 3 tick feeding placements, 2 to 8 weeks

apart. One to two punch skin biopsies (2-3 mm) from the tick bite sites will be collected at 1 day (early) and 2-4 days (late) after the first tick placement procedure. Skin biopsies of an unaffected site will be performed as a control. One to two punch skin biopsies (2-3 mm) from the tick bite sites will be collected at day 2-3 after the 2nd and 3rd tick placement procedures. Additionally, blood will be collected to evaluate systemic immune response to tick salivary proteins. Ticks will also be collected at each timepoint and gene expression will be analyzed to determine the effect of the human skin response on ticks.

Changes in resistance to tick bites can be evaluated by:

  • Local reaction to the tick bite

    • pruritus
    • site reactions
    • Blood flow index as measured by laser speckle contrast imaging
  • Number of fed ticks

Changes in the immune response and cellular recruitment in the skin can be evaluated using:

Differential expression of immune transcripts and other skin associated transcripts using RNAseq or other high-throughput profiling of cells.

Conventional histology and immunohistochemistry

Digital Spatial Profiling to determine cell type and other immune markers using a high-plex platform

Changes in the systemic immune response will be evaluated by:

Measurement of antibodies against tick salivary proteins will be assessed by enzyme-linked immunosorbent assay (ELISA) and

western blot

Novel state-of-the-art high-resolution technologies to deeply characterize the immune response to tick bites over time, both phenotypically and functionally.

Changes in tick transcriptomic profile will be assessed by:

RNAseq: Ribonucleic acid (RNA) will be isolated from tick after they have been removed from subjects and unexposed ticks.

Differential expression profile will be performed and validated by NanoString

Objectives:

Primary Objectives:

  1. Develop a model of acquired tick resistance in humans
  2. Continue to assess the safety of tick feeding using laboratory-reared Ixodes scapularis larva in humans

Exploratory Objectives:

  1. Comparison of the early and late immune response in the skin site of the bite of Ixodes scapularis after a single tick exposure.
  2. Determine the effects of repeated tick feeding on the immune response at the tick bite site in human skin and development of tick resistance.
  3. Analyze the evolution of the systemic immune response to tick bite in participants after multiple tick exposures and validate development of reliable biomarkers of tick exposure.
  4. Analyze gene expression of Ixodes scapularis larvae feeding on humans and determine the effects of immune response of subjects

repeatedly bitten on larvae gene expression.

Endpoints:

Primary Endpoints:

  1. Pruritus at the site of tick attachment in the first 24 hours of tick placement over the three placements as measured by a positive slope

    over the three placements of the numerical rating score. The slope of other pruritus scores at 24 hours and at Day 2-4, and the number of attached ticks collected from participants over the three placements will also be measured.

  2. Monitor safety adverse events (AEs) using reporting tools and Sponsor safety monitors.

Exploratory Endpoints:

  1. Compare the results from the skin biopsies acquired with the first tick placement. Our hypothesis is that there will be differential phenotypic, transcriptomic, and immunohistochemical differences between:

    • Exposed (bitten skin at day 1) and unexposed (unbitten skin)
    • Exposed (bitten skin at day 2-4) and unexposed (unbitten skin)
    • Exposed (bitten skin at day 1) and exposed (bitten skin at day 2-4)

    Measurement of changes will be assessed by:

    • Differential expression of immune transcripts and other skin associated transcripts using RNAseq
    • Conventional histology and immunohistochemistry
    • Digital Spatial Profiling to determine cell type and other immune markers using a high-plex platform
  2. Compare the changes in the local immune response and cellular recruitment between the 1st, 2nd and the 3rd tick exposures and correlate with measures of itching, blood flow index and number of attached ticks and the feeding status.

    We postulate that differences between the timepoints will become more marked with multiple exposures. We hypothesize that there will be differential phenotypic and transcriptomic differences between:

    Exposed (bitten skin at day 2-3, exposure 2) and exposed (bitten skin at day 2-3, exposure 3)

    Correlate these changes with measures of resistance to tick feeding (itching, number and level of feeding of attached ticks, blood flow index).

  3. Compare the development of antibody responses against Ixodes scapularis salivary protein antigens between the 1st, 2nd, and the 3rd tick exposures and correlate antibodies against tick salivary proteins with measures of resistance (itching, erythema, blood flow index, number of fed ticks).

    Explore the development of the host response in blood using high resolution technologies such as immunophenotyping, proteomics and

    transcriptomics and compare the responses between the 1st, 2nd, and the 3rd tick exposures.

  4. Using RNAseq technology, measure changes in gene expression of ticks fed at early timepoint (1 day) vs late timepoint (2-4 days) vs unfed ticks and of ticks fed at 1st, 2nd, and 3rd placements. Correlation of pruritus and changes in tick gene expression.
03

Conditions studied

  • Tick-borne Diseases
  • Tick Resistance
  • Lyme Disease

Browse trials for

Keywords

  • Tick Immunity
  • Tick-borne diseases
  • Vaccines
  • Lyme Disease
04

In context

Lyme Disease Reclassified

98 studies on the registry are indexed under Lyme Disease; 27 are open to participants now.

This study's planned enrollment of 60 is below the median of 120 across 52 interventional studies indexed under Lyme Disease.

Browse Lyme Disease studies →

Lead sponsor

National Institute of Allergy and Infectious Diseases (NIAID) is the lead sponsor of 2,449 studies on the registry; 181 are open to participants now.

Of its 406 completed or terminated interventional studies of FDA-regulated products, 303 (75%) have results posted.

Compared within Lyme Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Tick-Borne Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

  • INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  1. Stated willingness to comply with all study procedures and availability for the duration of the study.
  2. Age 18 years or older.
  3. In good general health as evidenced by medical history.
  4. No history of TBD.
  5. No known tick bite.
  6. Serum IgE level within Clinical Center Department of Laboratory Medicine normal range.

    https://ccinternal2.cc.nih.gov/LTGRA/UL/public_labtest_detail.aspx?next_flg=Y\&test_id=4731\&id_order=53

  7. Serum tryptase level within Clinical Center Department of Laboratory Medicine normal range.

    https://ccinternal2.cc.nih.gov/LTGRA/UL/public_labtest_detail.aspx?next_flg=Y\&test_id=1157\&id_order=1

  8. For participants of : use of effective for at least 1 month prior to tick placement, and agreement to use such a method during study participation and for an additional 3 months after the removal of the last ticks. Types of contraception include abstinence, surgical methods (sterilization, implants, intrauterine device, partner with vasectomy), hormonal methods (birth control pill, patch, ring, injection), or barrier methods (diaphragm plus spermicide, male condom plus spermicide)
  9. For males of : use of condoms or other methods to ensure effective contraception with partner.
  10. Agree to not participate in other clinical studies requiring interventions for the duration of the study.
  11. Minimum of 13.0 g/dL for males and 12 g/dL for females

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

  1. History of forming large thick scars (keloids) after skin injuries.
  2. History of excessive bleeding after cuts or procedures.
  3. History of taking anticoagulants in the past 28 days.
  4. History of allergic reaction to lidocaine.
  5. History of allergic reaction to tape, adhesive bandages, or dressings.
  6. Inability to maintain the dressing for any reason.
  7. Pregnancy or lactation.
  8. Treatment with another investigational drug or other intervention within the past 30 days.
  9. Oral or intravenous (IV) in the 2 weeks prior to each tick placement procedure (topical, nasal, inhaled, intra-articular, and replacement doses of steroids are not exclusions).
  10. History of reactions to mammalian meat, IgE- mediated food allergies, urticaria or anaphylaxis. Mild pollen-food allergy syndrome is not an exclusion.
  11. History of systemic allergic reaction to venom (bee, wasps and other Hymenoptera stings).
  12. History of drug allergies.
  13. History of moderate to severe atopy asthma, atopic dermatitis, allergic rhinitis.
  14. Active severe skin disease, uncontrolled diabetes, cancer other than non-melanoma skin cancers, disease requiring therapy, or history of (HIV), chronic viral hepatitis, or syphilis.
  15. Refusal to allow storage of samples and data for future usage.
  16. Any other condition that, in the opinion of the investigator, would make the patient unsuitable for enrollment or could interfere with the patient participating in and completing the study.

Exclusion of Select Populations:

Children:

Children are excluded from this protocol as there is no direct benefit to the participants, the risk from the skin is small but above minimal, the procedure is invasive and can be stressful for children, and there is concern over their ability to maintain the LeFlap dressing.

Pregnant and breastfeeding women:

Pregnant and breastfeeding women are excluded from trial participation as there is no direct benefit to the participants.

Adults who lack or lose decision-making capacity to consent to research participation:

Adults lacking decision-making capacity to provide are excluded at screening as there is no direct benefit to the participants. Enrolled participants who permanently or temporarily lose the ability to consent after receiving the first tick exposure procedure will be advised to continue study visits for safety monitoring but will have no additional research procedures performed.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    1

    Healthy Volunteer

    Device: Xenodiagnosis Ticks · Procedure: skin biopsy · Procedure: blood draw

Interventions

  • DeviceXenodiagnosis Ticks

    Larval ticks will be obtained from Dr. Sam Telford from a laboratory maintained tick colony at Tufts Veterinary School. These ticks are hatched from eggs laid by ticks that have fed only on specific pathogen free laboratory animals that were purchased from established vendors.

  • Procedureskin biopsy

    2-3 mm skin punch biopsies will be performed.

  • Procedureblood draw

    Peripheral blood draws will be performed.

07

What researchers measure

Primary outcomes

  1. Assessment of Safety of the device. Use toxicity tables and safety monitoring as specified in the protocol.

    Ongoing assessment of safety.

    Time frame: continuous

  2. Develop a model of acquired tick resistance in humans. Use validated pruritus scales, numerical rating system, verbal rating system, and visual analogue system.

    Clinical measures of tick immunity.

    Time frame: end of study

Secondary outcomes

  1. Exploratory: Determine the effects of repeated tick feeding on immune response at tick bite site and the development of resistance. Use RNASeq,histology, immunohistochemistry, digital spatial profiling, clinical itch scales, site reactions, tick...

    Compare changes in early and late local immune response and cellular recruitment between the 1st and 3rd tick exposures.

    Time frame: continuous

  2. Exploratory: Analyze gene expression of Ixodes scapularis after feeding on humans using RNASeq.

    Measure changes in gene expression of ticks fed at the various time points.

    Time frame: continuous

  3. Exploratory: Compare early and late immune response in skin after Ixodes scapularis bite. Use RNASeq, histology, immunohistochemistry, digital spatial profiling to explore.

    Compare early and late immune response in the skin using skin biopsies collected at Day 1 and Day 4.

    Time frame: continuous

  4. Exploratory: Analyze the evolution of the systemic immune response to tick bite by measuring antibodies response (ELISA and western blot) against Ixodes scapularis salivary protein antigens.

    Compare the development of antibody responses against Ixodes scapularis salivary antigens between the 1st, 2nd, and 3rd tick feedings.

    Time frame: continous

08

Study locations

1 of 1 sites recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
    • For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) · Contactprpl@cc.nih.gov · 800-411-1222
09

References and documents

Publications

  • Marques A, Telford SR 3rd, Turk SP, Chung E, Williams C, Dardick K, Krause PJ, Brandeburg C, Crowder CD, Carolan HE, Eshoo MW, Shaw PA, Hu LT. Xenodiagnosis to detect Borrelia burgdorferi infection: a first-in-human study. Clin Infect Dis. 2014 Apr;58(7):937-45. doi: 10.1093/cid/cit939. Epub 2014 Feb 11. PubMed 24523212 ↗
  • Ribeiro JM, Alarcon-Chaidez F, Francischetti IM, Mans BJ, Mather TN, Valenzuela JG, Wikel SK. An annotated catalog of salivary gland transcripts from Ixodes scapularis ticks. Insect Biochem Mol Biol. 2006 Feb;36(2):111-29. doi: 10.1016/j.ibmb.2005.11.005. Epub 2005 Dec 20. PubMed 16431279 ↗
  • Valenzuela JG. Exploring tick saliva: from biochemistry to 'sialomes' and functional genomics. Parasitology. 2004;129 Suppl:S83-94. doi: 10.1017/s0031182004005189. PubMed 15938506 ↗

Individual participant data

Plan to share: Undecided — It is not yet known if the research results will reveal a need to disclose IPD, therefore it is undecided if we plan to make IPD available.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2022 (actual). Primary completion is estimated for Jun 2029, 88 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2021
First posted
Sep 8, 2021
StartActual
Feb 28, 2022
Primary completionEst.
Jun 30, 2029
CompletionEst.
Jun 30, 2029
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05036707
Responsible party
Sponsor
First posted
Sep 8, 2021
Start date
Feb 28, 2022
Primary completion
Jun 30, 2029 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Sep 22, 2026

Study contacts

Siu-Ping Ng, R.N.
Contact
sturk1@mail.nih.gov
(301) 451-7661
Adriana R Marques, M.D.
Contact
amarques@niaid.nih.gov
(301) 435-7244
Adriana R Marques, M.D.
principal investigator · National Institute of Allergy and Infectious Diseases (NIAID)

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion